Wednesday, July 8, 2026
🇺🇸 FDA

Drug profile · INN

lesinurad

ZURAMPIC

lesinurad (ZURAMPIC) is a solute carrier family 22 member 12 inhibitor. Associated with IRONWOOD PHARMACEUTICALS INC. Route of administration: oral. Current US regulatory status: approved.

FDA: approved EMA: withdrawn Musculo-skeletal system (M04) M04AB05
US status approved
Patents linked 19
Pipeline programs 1
News articles 0
Drug details — lesinurad
US status
approved
Class
Musculo-skeletal system (M04)
Route
ORAL
Patents
19
Programs
1
Data quality
0.89
← All drugs Manufacturer profile Related patents Pipeline programs Drug news hub Event calendar

Quick answer

lesinurad (ZURAMPIC) is a solute carrier family 22 member 12 inhibitor. Associated with IRONWOOD PHARMACEUTICALS INC. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN lesinurad
Brand ZURAMPIC
Mechanism Solute carrier family 22 member 12 inhibitor
Target Solute carrier family 22 member 12
Therapeutic class Musculo-skeletal system (M04)
Route ORAL
Formulation TABLET
ATC code M04AB05
Originator IRONWOOD PHARMACEUTICALS INC

Mechanism of action

Solute carrier family 22 member 12 inhibitor

Primary target: Solute carrier family 22 member 12

Approval history

Authority Status Date
FDA approved —
EMA withdrawn —

Pipeline programs

Search pipeline Sponsor programs
  1. Lesinurad Approved · IRONWOOD PHARMACEUTICALS · Gout

Related & competitor drugs

Browse all drugs
  1. allopurinol Musculo-skeletal system (M04)
  2. colchicine Musculo-skeletal system (M04)
  3. denosumab Musculo-skeletal system (M05)
  4. eteplirsen Musculo-skeletal system (M09)
  5. febuxostat Musculo-skeletal system (M04)
  6. ibandronic acid Musculo-skeletal system (M05)

Related patents

Browse patents IRONWOOD PHARMACEUTICALS INC patent hub

  1. US 11365180

    Resolution method for axis chiral enantiomers of lesinurad

    Expires Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10266529

    Salts, co-crystals, and polymorphs of an anxiolytic compound

    Expires Mon Apr 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10189809

    SGC stimulators

    Expires Mon Jan 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10183021

    sGC stimulators

    Expires Mon Jan 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10047095

    sGC stimulators

    Expires Mon Aug 09 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 9969742

    Imidazotriazinone compounds

    Expires Mon May 10 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 9745296

    Salts, co-crystals, and polymorphs of an anxiolytic compound

    Expires Mon Aug 24 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 9725453

    Imidazotriazinone compounds

    Expires Mon Aug 03 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 9586937

    sGC stimulators

    Expires Mon Mar 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 9540380

    Imidazotriazinone compounds

    Expires Mon Jan 05 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 9487508

    SGC stimulators

    Expires Mon Nov 03 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 9481689

    sGC stimulators

    Expires Mon Oct 27 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 9309235

    SGC stimulators

    Expires Mon Apr 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 9139564

    2-benzyl, 3-(pyrimidin-2-yl) substituted pyrazoles useful as sGC stimulators

    Expires Mon Sep 17 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 9061030

    sGC stimulators

    Expires Mon Jun 18 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 8884020

    Indole compounds

    Expires Mon Nov 06 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 8748442

    sGC stimulators

    Expires Mon Jun 05 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 8674115

    CRTH2 modulators

    Expires Mon Mar 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 7494979

    Method for treating congestive heart failure and other disorders

    Expires Mon Feb 19 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is lesinurad?

lesinurad (ZURAMPIC) is a solute carrier family 22 member 12 inhibitor. Associated with IRONWOOD PHARMACEUTICALS INC. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for lesinurad?

ZURAMPIC is a marketed brand name for lesinurad. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of lesinurad?

lesinurad has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.